Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry

Canonica, Giorgio Walter; Malvezzi, Luca; Blasi, Francesco; Paggiaro, Pierluigi; Mantero, Marco; Senna, Gianenrico; Heffler, Enrico; Bonavia, Marco; Caiaffa, P.; Calabrese, Cecilia; Camiciottoli, Gianna; Caruso, Cristiano; Centanni, Stefano; Conte, Maria Elisabetta; Corsico, Angelo Guido; Cosmi, Lorenzo; Costantino, Maria Teresa; Crimi, Nunzio; D’Alò, S.; D’Amato, Maria; Giacco, Stefano Del; Favero, Elisabetta; Farsi, Alessandro; Foschino, B.P.M.; Guarnieri, Gabriella; Guida, Giuseppe; Latorre, Manuela; Lombardi, Carlo; Macchia, Luigi; Menzella, Francesco; Milanese, Manlio; Montuschi, Paolo; Nucera, Eleonora; Parente, Roberta; Passalacqua, Giovanni; Patella, Vincenzo; Pelaia, Girolamo; Pini, Laura; Ricciardolo, Fabio Luigi Massimo; Ricciardi, Luisa; Richeldi, Luca; Ridolo, Erminia; Rolla, Giovanni; Santus, Pierachille; Scichilone, Nicola; Solidoro, Paolo; Spadaro, Giuseppe; Spanevello, Antonio; Vianello, Andrea; Yacoub, Mona‐Rita; Zappa, Maria Cristina

doi:10.1016/j.rmed.2020.105947

Cited by 61 publications

(51 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In non‐atopic asthma and late‐onset asthma, CRSwNP was found frequently, reaching 15% to 26% depending on the study 149 . Even more, in severe asthmatic patients the prevalence of CRSwNP can reach up to 40.6% 1348 …”

Section: Chronic Rhinosinusitis With Nasal Polyps (Crswnp)mentioning

confidence: 98%

International consensus statement on allergy and rhinology: rhinosinusitis 2021

Orlandi

Kingdom

Smith

et al. 2021

Int Forum Allergy Rhinol

422

465

View full text Add to dashboard Cite

I. Executive Summary Background The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR‐RS‐2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence‐based findings of the document. Methods ICAR‐RS presents over 180 topics in the forms of evidence‐based reviews with recommendations (EBRRs), evidence‐based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary. Results ICAR‐RS‐2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence‐based management algorithm is provided. Conclusion This ICAR‐RS‐2021 executive summary provides a compilation of the evidence‐based recommendations for medical and surgical treatment of the most common forms of RS.

show abstract

Section: Chronic Rhinosinusitis With Nasal Polyps (Crswnp)mentioning

confidence: 98%

International consensus statement on allergy and rhinology: rhinosinusitis 2021

Orlandi

Kingdom

Smith

et al. 2021

Int Forum Allergy Rhinol

422

465

View full text Add to dashboard Cite

show abstract

“…The presence of nasal polyposis accounted for a significant higher OCS use (double days/year on OCSs) with respect to SA patients without nasal polyposis. 42 Once again, we need to highlight how a detailed evaluation/analysis of the real-life data coming from registries can provide challenging information, leading to a change in the treatment algorithms in clinical practice. Table 1 summarizes the already published data derived from the SANI registry, focusing the attention on the use of OCSs in severe asthmatics, and evidence from the literature on the OCS sparing effect of the main biologics used for treating severe asthma.…”

Section: Severe Asthma Network Italy (Sani) Related Findingsmentioning

confidence: 99%

“…– WAO J 2019 38 Pharmacoeconomic model to assess OCS-related adverse events cost in severe asthmatics: 92.7 milion Euro estimated for the entire severe asthmatic Italian population; 41.5 milion Euro estimated incremental expenditure compared to non-asthmatics 26.3 milion Euro estimated incremental expenditure compared to moderate-asthmatics Canonica GW et al. – Respir Med 2020 42 n = 695mean age: 54.9 yearsmean age of asthma onset: 33.7 years60.6% females;75.9% atopics;Prevalence of CRSwNP: 40.6%; patients with CRSwNP had: higher annual exacerbation rate (3.69 vs 2.46) higher prevalence of bronchiectasis (20.9 vs 11.9) higher FENO (54.4 vs 34.6) lower serum IgE (379.4 vs 533.3) higher frequency of long-term OCS use (60.6% vs 37.3%) higher number of days/year in OCS treatment (161.4 vs 78.9) Literature evidence showing OCS sparing effect of the main biologics used for severe asthma Article Main results Braunstahl GJ et al. Allergy Asthma Clin Immunol 2013 47 Biological agent: Omalizumab.Data from “eXpeRience”, a multinational, observational registry.n = 69428.6% of patients were taking OCS at baseline.…”

Section: Main Textmentioning

confidence: 99%

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

Canonica

Blasi

Paggiaro

et al. 2020

World Allergy Organization Journal

Self Cite

View full text Add to dashboard Cite

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managing corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should be considered a primary outcome in the management of severe asthma. New biologics have clearly demonstrated that this effect is possible, with concomitant reduction in the rate of exacerbations and in symptom control. Then, there is no reason for using so frequently oral corticosteroid before having explored all alternatives currently available for a large part of severe asthmatics.

show abstract

“…Anti-inflammatory therapies are at the forefront in the treatment of eosinophilic CRSwNP (E-CRSwNP) and, above all, corticosteroids, both intranasal and systemic (they contrast type 2 inflammation thus controlling both local and associated systemic effects of the disease) [37]. However, chronic and/or recurrent use of both systemic corticosteroids (particularly frequent in patients with CRSwNP and concomitant severe asthma [38]) and topical corticosteroids is associated with a relevant increased risk to develop adverse events (i.e. : type-2 diabetes, hypertension, glaucoma, osteoporosis.…”

Section: Surgical Management: Contemporary and Future Perspectivementioning

confidence: 99%